Sandoz Sanguine On Market Opportunity Despite Biosimilar Neulasta Setback

 
• By Lucie Ellis-Taitt

Questions from European regulators around Sandoz's market application for biosimilar pegfilgrastim have prompted the company to withdraw the drug's filing – a delay which could allow competitor biosimilar developers to launch ahead of the Novartis-owned company.

Illustration of an European Union long shadow flag with a weight scale
Sandoz withdraws European marketing application for biosimilar pegfilgrastim • Source: Shutterstock

More from New Products

More from Scrip